Espansione Group

22/01/2026

Mucus Fishing Syndrome (MFS) is a chronic inflammatory condition of the ocular surface, characterized by repetitive mechanical removal of mucus that perpetuates inflammation and epithelial damage. ​

In a recent case series Mancini et al. (2025), prove the effectiveness of LM™ LLLT Photobiomodulation as an adjunctive therapy for the multimodal management of MFS.​

In this study, two patients with persistent MFS, refractory to conventional therapy, showed significant improvements in tear film stability, mucus reduction and ocular discomfort after LM™ LLLT.​

These preliminary results indicate that LM™ LLLT holds significant potential in the management of complex ocular surface conditions such as MFS, supporting its broader applicability across ocular surface care.​

👉 Read the full paper : https://pubmed.ncbi.nlm.nih.gov/41487120/

12/12/2025

As the year comes to an end, we are excited to unveil the first new appointments for the 2026 In-Sight Webinar Series featuring fresh scientific insights across retinal and ocular surface disease.

Starting this month, the series will feature new sessions derived from our ESCRS and EURETINA 2025 scientific coverage, including:

•AMD & Photobiomodulation: The evolving role of mitochondrial health and PBM therapy
•Dry Eye in Surgical Candidates: Light Therapy for Tear Film Optimization in the Vision Correction Surgery Workflows
•Managing Ocular Surface Health in Glaucoma Patients: LM™ LLLT to Restore Tear Film, Relieve Symptoms and increase QOL
•TFOS DEWS III Deep Dive: What's New with the Global Consensus in the Ocular Surface Disease: Diagnosis to Treatment
•Long-Term Management of MGD Dry Eye: Evidence-based Triple-therapy for Chronic Care

Why attend?
These webinars deliver practical, clinically actionable insights to help you navigate the latest diagnostic and therapeutic pathways.

This is only the beginning—more expert-led episodes will follow soon.

Explore the new series and secure your seat for upcoming sessions.
👉 Register now: https://app.livestorm.co/espansione-group?lang=en

08/12/2025

Floretina 2025 has wrapped up, leaving us with fresh ideas, meaningful clinical insights and a renewed sense of purpose.

The discussions around light-based technologies — including LM™ LLLT (PBM) — and data-driven approaches were particularly inspiring and strengthened our commitment to supporting the scientific community with robust evidence and real-world clinical outcomes.

A heartfelt thank you to our outstanding team for their dedication and energy throughout the congress.

We are also deeply grateful to our KOLs — Claudio Iovino, Sibel Demirel, Pasquale Viggiano, Kelvin Teo, Enrico Borrelli and Rosa Dolz Marco — for their continued trust in LM™ LLLT (PBM) and for taking the time to engage with us and share their perspectives.
It is a privilege to collaborate with experts who are actively shaping the future of retinal care.

Our appreciation also extends to our colleagues at EssilorLuxottica, Heidelberg Engineering and RetinAI, whose collaboration and shared commitment to innovation remain invaluable

We leave Florence energized, aligned and more focused than ever on advancing evidence-based, light-driven technologies that address the clinical needs shaping the future of retinal care.

06/12/2025

How can non-invasive PBM support retinal microcirculation and visual function in intermediate AMD?

Tomorrow at FLORetina 2025, Dr. Mariapia Laterza will present new insights on how LM™ LLLT Photobiomodulation (PBM) may enhance retinal microcirculation and low-light vision in intermediate AMD.

📅 Sunday, December 7th — 10:09
📍 Del Carmine Room

Her session highlights PBM’s potential as a safe, non-invasive approach to support retinal health at a stage where therapeutic options are still limited.

Stop by Booth #56 to explore what’s next in non-invasive retinal care.

05/12/2025

How can non-invasive light-based therapy support early-stage AMD?

Discover the answer at FLORetina 2025 during Dr. Claudio Iovino's session on the LightWave I, a multicenter, randomized, double-masked clinical trial exploring LM™ LLLT Photobiomodulation (PBM) in early and intermediate dry AMD.

📅 Saturday, December 6th — 14:28
📍 San Giovanni Room

Dr. Claudio Iovino will discuss how PBM may offer a safe, non-invasive way to manage early structural and functional changes in dry AMD, at a stage where few therapeutic options exist.

Stop by Booth #56 to learn more about the future of non-invasive retinal care.

27/11/2025

We’re looking forward to seeing you all at FLORetina 2025.

After achieving great resonance in Anterior Segment care, we are bringing our core light-based technology LM™ LLLT Photobiomodulation (PBM) to the back of the eye.

If you share our ambition to slow down progression of the disease, stop by 📍 Booth #56 and join us on our mission to advance non-invasive management of Age-related Macular Degeneration.

📅 Curious to learn more?
👇 Don’t miss this year’s faculty sessions on our technology.

Dr. Claudio Iovino
"12-Months Outcomes of PBM in Intermediate AMD: A Prospective Multicenter Randomized Controlled Clinical Trial

🗓️ Saturday, December 6th
🕒 14:28
📍 San Giovanni Room

Dr. Mariapia Laterza
"Photobiomodulation-induced Choriocapillaris Perfusion Enhancement and Outer Retinal Remodelling in Intermediate Age-Related Macular Degeneration: a Promising Therapeutic Approach with Short-term Results"

🗓️ Sunday, December 7th
🕒 10:09
📍 Del Carmine Room

⚡️One more thing...

This year at FLORetina 2025 we’re joined by our colleagues from EssilorLuxottica, Heidelberg Engineering and Retinai .

👉 Come and join us in shaping what’s next in ​ophthalmology—we can’t wait to see you all in Florence.

06/11/2025

The ocular microbiome is central to ocular surface health, and Demodex infestation is a major driver of blepharitis and dry eye disease.

A new peer-reviewed study (Farrant S. et al., Clin Ophthalmol. 2025) demonstrates the effectiveness of eye-light® combining OPE™ IPL and LM™ LLLT (blue + red light) in managing treatment-resistant Demodex blepharitis.

Key outcomes:
✅ Significant reduction in collarettes & saponification
✅ Improved ocular surface parameters (CFS, hyperemia)
✅ Symptom relief (DEQ-5 ↓ from 12.0 → 7.8)
✅ No adverse events reported

By targeting both mite eradication and ocular surface health, our light-based protocol offers a comprehensive, safe, and patient-friendly solution for Demodex blepharitis.

At Espansione, we remain committed to advancing evidence-based innovation in ophthalmology.

23/10/2025

A breakthrough in ocular surface protection: results from a randomized, double-masked trial highlight the effectiveness of LM™ LLLT (PBM) in reducing Iatrogenic Dry Eye Disease after cataract surgery.

Conducted on a real-life surgical cohort, the therapy was safe, feasible to implement perioperatively, and readily adaptable to standard cataract surgery protocols.

The study found statistical significance in the following results:
✅ Improvements in OSDI and tear film break-up time
✅ Stabilization of tear osmolarity
✅ Preservation of corneal epithelial integrity

This reinforces the importance of device-based, non-invasive therapies in modern ophthalmology and sets a foundation for the integration of LM™ LLLT into routine surgical care.

Acknowledging the outstanding work of the authors: Mihaela-Madalina Timofte-Zorila, Daniel Constantin Branisteanu & team.

14/10/2025

This weekend in Taunton reminded us of the power of collaboration and shared expertise.

Our sincere thanks to Rodenstock Norway and Olav Bjella Stavn for bringing together an engaged group of Norwegian optometrists and to Dr. Sarah Farrant for welcoming everyone into her clinic and sharing her clinical experience with eye-light® and Light Modulation™ LLLT.

From theory to real-world application, participants had the opportunity to witness firsthand how light-based therapies are transforming the management of dry eye and ocular surface diseases — guided by Dr. Farrant's deep expertise and daily clinical practice.

Our warmest thanks to Dr. Sarah Farrant for opening her doors and sharing her insights, to Rodenstock and Olav Bjella Stavn for their amazing collaboration, to our one and only Riccardo Nicoletti for being our rock, and to all participants for bringing their enthusiasm and curiosity.

Together, we continue to advance science-based innovation in eye care.

14/09/2025

11/09/2025

🔬 1 Day to Go | Join Us at ESCRS 2025
📍 Hall C · Booth C1.180

Tomorrow at ESCRS, we launch the InSight Speech Series—a daily program of live scientific talks hosted at our booth, featuring leading voices in ocular innovation.

🎤 Join Prof. Giannaccare, Dr. Daya, Prof. Wolffsohn, Dr. Trave-Huarte, Prof. Piñero, Dr. Stonecipher, Dr. Timofte, Dr. Valdez-Garcia and others as they share clinical insights on:
✅ TFOS DEWS III Report & Dry Eye
✅ Surgical outcomes & post-op DED
✅ Ocular microbiome & LLLT
✅ Demodex blepharitis
✅ PBM for AMD: multicentric data
✅ Screening innovation in ocular surface care

Whether you’re focused on the ocular surface or retinal therapy, this is where science meets practice—live.

👉 View the full agenda & add to your calendar:
https://espansionegroup.it/espansione-group-at-escrs-2025/

Let’s move science forward.
See you tomorrow at Booth C1.180.

04/09/2025

Just one day to go—discover one of the standout session of the Euretina 2025 Congress.

You're invited to join our expert-led symposium:

Light Modulation™ LLLT (PBM): A New Frontier in Retinal Care & Beyond
🗓 September 5th | 🕔 17:45–18:45
📍 Amphithéâtre Havane, Level 3, Le Palais des Congrès, Paris

🎓 Speakers: Prof. Giannaccare | Prof. Demirel | Prof. Borrelli | Dr. Iovino | Dr. Viggiano
🎤 Moderators: Dr. Bacherini | Prof. Zur | Prof. Mastropasqua

In this one-hour session, we’ll explore the science, mechanisms, and clinical evidence behind PBM as a non-invasive therapeutic strategy for Dry Age-related Macular Degeneration and beyond.

Also happening at Euretina 2025:
- Prof. Borrelli (Italy) ePoster: 12-Month Efficacy of Photobiomodulation Treatment in Dry Age-Related Macular Degeneration Using the eye-light® Device” | ePoster & Video Terminals on Level 3

🔗 Explore the full program and join us in Paris to discover the future of light-based retinal therapy.

📌 Visit us throughout the congress at EssilorLuxottica Booth 3.A25